MD3883606T2 - Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23 - Google Patents
Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23Info
- Publication number
- MD3883606T2 MD3883606T2 MDE20210930T MDE20210930T MD3883606T2 MD 3883606 T2 MD3883606 T2 MD 3883606T2 MD E20210930 T MDE20210930 T MD E20210930T MD E20210930 T MDE20210930 T MD E20210930T MD 3883606 T2 MD3883606 T2 MD 3883606T2
- Authority
- MD
- Moldova
- Prior art keywords
- ulcerative colitis
- antibody
- safe
- effective method
- treating ulcerative
- Prior art date
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title abstract 3
- 201000006704 Ulcerative Colitis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 102000013264 Interleukin-23 Human genes 0.000 title 1
- 108010065637 Interleukin-23 Proteins 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Sunt descrise metode şi compoziţii pentru tratamentul sigur şi eficient dovedit clinic, al colitei ulcerative, în special al colitei ulcerative active moderată până la severă, la pacienţii care au avut un răspuns inadecvat la, sau sunt intoleranţi la o terapie convenţională sau existentă, prin administrare intravenoasă şi/sau subcutanată a unui anticorp anti-IL-12/IL-23p40.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862735501P | 2018-09-24 | 2018-09-24 | |
US201862769818P | 2018-11-20 | 2018-11-20 | |
US201962895774P | 2019-09-04 | 2019-09-04 | |
PCT/IB2019/058098 WO2020065532A1 (en) | 2018-09-24 | 2019-09-24 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
MD3883606T2 true MD3883606T2 (ro) | 2023-12-31 |
MD3883606T3 MD3883606T3 (ro) | 2024-03-31 |
Family
ID=69885324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20210930T MD3883606T3 (ro) | 2018-09-24 | 2019-09-24 | Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23 |
Country Status (23)
Country | Link |
---|---|
US (3) | US10961307B2 (ro) |
EP (1) | EP3883606B9 (ro) |
JP (3) | JP7359845B2 (ro) |
KR (2) | KR20210064315A (ro) |
CN (1) | CN113164596A (ro) |
AU (8) | AU2019346134C1 (ro) |
BR (1) | BR112021005467A2 (ro) |
CA (2) | CA3113837C (ro) |
DE (1) | DE202019006083U1 (ro) |
DK (3) | DK3883606T5 (ro) |
ES (1) | ES2959463T3 (ro) |
FI (2) | FI13575Y1 (ro) |
HR (1) | HRP20230886T1 (ro) |
HU (1) | HUE063462T2 (ro) |
IL (1) | IL281642A (ro) |
LT (1) | LT3883606T (ro) |
MD (1) | MD3883606T3 (ro) |
MX (1) | MX2021003411A (ro) |
PL (1) | PL3883606T3 (ro) |
PT (1) | PT3883606T (ro) |
RS (1) | RS64552B9 (ro) |
SI (1) | SI3883606T1 (ro) |
WO (1) | WO2020065532A1 (ro) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2959463T3 (es) | 2018-09-24 | 2024-02-26 | Janssen Biotech Inc | Método seguro y eficaz para tratar la colitis ulcerativa con anticuerpo anti-il12/il23 |
BR112021023295A2 (pt) | 2019-05-23 | 2022-02-08 | Janssen Biotech Inc | Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa |
CA3158202A1 (en) * | 2019-10-18 | 2021-04-22 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
EP4146273A4 (en) * | 2020-05-05 | 2024-07-31 | Janssen Biotech Inc | METHODS OF TREATING CROHN'S DISEASE USING A SPECIFIC ANTI-IL23 ANTIBODY |
US20220025035A1 (en) * | 2020-07-13 | 2022-01-27 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody |
WO2022024065A1 (en) * | 2020-07-30 | 2022-02-03 | Janssen Biotech, Inc. | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody |
US20220102008A1 (en) * | 2020-09-30 | 2022-03-31 | Genentech, Inc. | Methods and systems for placebo response modeling |
TW202246329A (zh) * | 2021-03-03 | 2022-12-01 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
CN117940163A (zh) * | 2021-07-26 | 2024-04-26 | 阿瓦洛治疗公司 | 用抗light抗体治疗溃疡性结肠炎的方法 |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
AU4434585A (en) | 1985-03-30 | 1986-10-23 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
EP0349578B2 (en) | 1987-03-02 | 1998-10-28 | Enzon Labs Inc. | Organism carrying a Single Chain Antibody Domain at its surface. |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
DE68926882T2 (de) | 1988-01-11 | 1997-02-13 | Xoma Corp | Plasmidvektor mit pectatlyase-signalsequenz |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US4987893A (en) | 1988-10-12 | 1991-01-29 | Rochal Industries, Inc. | Conformable bandage and coating material |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ATE140483T1 (de) | 1988-11-10 | 1996-08-15 | Genetics Inst | Natürlicher killerzellen-stimulationsfaktor |
US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
ATE168416T1 (de) | 1989-10-05 | 1998-08-15 | Optein Inc | Zellfreie synthese und isolierung von genen und polypeptiden |
EP0790255B1 (en) | 1989-12-22 | 2007-08-08 | F. Hoffmann-La Roche Ag | Monoclonal antibodies directed to the cytotoxic lymphocyte maturation factor |
US6683046B1 (en) | 1989-12-22 | 2004-01-27 | Hoffmann-La Roche Inc. | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
WO1992003461A1 (en) | 1990-08-24 | 1992-03-05 | Ixsys, Inc. | Methods of synthesizing oligonucleotides with random codons |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
JP3298879B2 (ja) | 1990-12-20 | 2002-07-08 | イグジス,インコーポレイテッド | 結合タンパク質の最適化 |
DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
WO1994018219A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US5770428A (en) | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
DE4315127A1 (de) | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
SE9304060D0 (sv) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
CA2188543A1 (en) | 1994-04-22 | 1995-11-02 | Steven G. Reed | Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production |
US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
WO1996013583A2 (en) | 1994-10-20 | 1996-05-09 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Targeted hetero-association of recombinant proteins to multi-functional complexes |
US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質/(ポリ)ペプチドライブラリー |
US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
DE19624387C2 (de) | 1996-06-19 | 1999-08-19 | Hatz Motoren | Kaltstartvorrichtung |
GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
WO1998034635A1 (en) | 1997-02-07 | 1998-08-13 | The Wistar Institute | Methods and compositions for the inhibition of interleukin-12 production |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
AU8691398A (en) | 1997-08-04 | 1999-02-22 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
AU750567B2 (en) | 1997-09-29 | 2002-07-25 | Novartis Ag | Stabilized preparations for use in nebulizers |
CN100374466C (zh) | 1998-01-23 | 2008-03-12 | 霍夫曼-拉罗奇有限公司 | 人il-12抗体 |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
AU1843200A (en) | 1998-12-09 | 2000-06-26 | Protein Design Labs, Inc. | Animal model for psoriasis for the prevention and treatment of psoriasis in humans |
PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
TR200501367T2 (tr) | 1999-03-25 | 2005-09-21 | Abbott Gmbh & Co. Kg | Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler. |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
AU7127600A (en) | 1999-09-17 | 2001-04-17 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
AU2002307037B2 (en) | 2001-04-02 | 2008-08-07 | Biogen Idec Inc. | Recombinant antibodies coexpressed with GnTIII |
JP2005524379A (ja) | 2001-08-03 | 2005-08-18 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性の増強を伴う抗体グリコシル化改変体 |
JP2007515939A (ja) | 2003-05-09 | 2007-06-21 | セントカー・インコーポレーテツド | IL−23p40特異的免疫グロブリン由来タンパク質、組成物、方法および用途 |
CN103146708A (zh) | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
US20090181027A1 (en) | 2007-09-28 | 2009-07-16 | Paul Dal Monte | Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses |
US8853365B2 (en) * | 2010-12-21 | 2014-10-07 | Abbvie Inc. | Dual variable domain immunnoglobulins and uses thereof |
CA2998349A1 (en) * | 2015-09-17 | 2017-03-23 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
CA3007098A1 (en) * | 2015-12-22 | 2017-06-29 | Amgen Inc | Ccl20 as a predictor of clinical response to il23-antagonists |
JP7237834B2 (ja) * | 2016-12-14 | 2023-03-13 | ビオラ・セラピューティクス・インコーポレイテッド | 消化管疾病のil-12/il-23阻害薬による治療 |
ES2959463T3 (es) | 2018-09-24 | 2024-02-26 | Janssen Biotech Inc | Método seguro y eficaz para tratar la colitis ulcerativa con anticuerpo anti-il12/il23 |
-
2019
- 2019-09-24 ES ES19867085T patent/ES2959463T3/es active Active
- 2019-09-24 DE DE202019006083.9U patent/DE202019006083U1/de active Active
- 2019-09-24 CA CA3113837A patent/CA3113837C/en active Active
- 2019-09-24 BR BR112021005467-7A patent/BR112021005467A2/pt unknown
- 2019-09-24 FI FIU20230063U patent/FI13575Y1/fi unknown
- 2019-09-24 HR HRP20230886TT patent/HRP20230886T1/hr unknown
- 2019-09-24 HU HUE19867085A patent/HUE063462T2/hu unknown
- 2019-09-24 WO PCT/IB2019/058098 patent/WO2020065532A1/en active Application Filing
- 2019-09-24 SI SI201930606T patent/SI3883606T1/sl unknown
- 2019-09-24 KR KR1020217012128A patent/KR20210064315A/ko not_active IP Right Cessation
- 2019-09-24 MX MX2021003411A patent/MX2021003411A/es unknown
- 2019-09-24 EP EP19867085.3A patent/EP3883606B9/en active Active
- 2019-09-24 US US16/580,509 patent/US10961307B2/en active Active
- 2019-09-24 FI FIEP19867085.3T patent/FI3883606T3/fi active
- 2019-09-24 MD MDE20210930T patent/MD3883606T3/ro unknown
- 2019-09-24 KR KR1020237034949A patent/KR20230148273A/ko active Application Filing
- 2019-09-24 DK DK19867085.3T patent/DK3883606T5/da active
- 2019-09-24 AU AU2019346134A patent/AU2019346134C1/en active Active
- 2019-09-24 CN CN201980077285.XA patent/CN113164596A/zh active Pending
- 2019-09-24 PL PL19867085.3T patent/PL3883606T3/pl unknown
- 2019-09-24 CA CA3160103A patent/CA3160103A1/en active Pending
- 2019-09-24 LT LTEPPCT/IB2019/058098T patent/LT3883606T/lt unknown
- 2019-09-24 RS RS20230705A patent/RS64552B9/sr unknown
- 2019-09-24 PT PT198670853T patent/PT3883606T/pt unknown
- 2019-09-24 JP JP2021515167A patent/JP7359845B2/ja active Active
-
2021
- 2021-02-11 US US17/174,201 patent/US20210171622A1/en not_active Abandoned
- 2021-03-18 IL IL281642A patent/IL281642A/en unknown
-
2022
- 2022-12-22 JP JP2022205509A patent/JP7481423B2/ja active Active
-
2023
- 2023-02-28 AU AU2023201217A patent/AU2023201217A1/en active Pending
- 2023-05-18 AU AU2023100041A patent/AU2023100041B4/en active Active
- 2023-05-18 AU AU2023100042A patent/AU2023100042B9/en active Active
- 2023-07-11 DK DKBA202300038U patent/DK202300038Y9/da active IP Right Grant
- 2023-08-17 JP JP2023133026A patent/JP2023162273A/ja active Pending
- 2023-10-24 US US18/383,310 patent/US20240182557A1/en active Pending
-
2024
- 2024-02-21 AU AU2024100006A patent/AU2024100006B4/en active Active
- 2024-02-21 AU AU2024100007A patent/AU2024100007B4/en active Active
- 2024-03-21 AU AU2024100016A patent/AU2024100016B4/en active Active
- 2024-03-21 AU AU2024100017A patent/AU2024100017A4/en active Active
- 2024-04-18 DK DKBA202400026U patent/DK202400026U1/da unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3883606T3 (ro) | Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23 | |
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
MX2022015499A (es) | Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. | |
SG10201807070YA (en) | Respiratory mask with nasogastric tube path | |
EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
EA201691420A1 (ru) | Композиции енолазы 1 (eno1) и их применение | |
CO2021006290A2 (es) | Dosificación subcutánea y administración de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh) | |
EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
CO2021016606A2 (es) | Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple | |
MX2022013923A (es) | Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23. | |
WO2017189906A8 (en) | Immune-based treatment of kras-variant cancer patients | |
MX2023004017A (es) | Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23. | |
MX2022001153A (es) | Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab. | |
MX2022004581A (es) | Método seguro y eficaz para tratar la colitis ulcerosa con el anticuerpo anti-il12/il23. | |
MX2022009987A (es) | Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. | |
AR111491A1 (es) | Métodos para tratar enfermedades pediátricas | |
MX2023000732A (es) | Anticuerpos anti- alfa-4-beta-7. | |
MX2024005860A (es) | Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23. | |
PL433279A1 (pl) | Metoda leczenia osób zakażonych KORONAWIRUS-em | |
JOP20210347A1 (ar) | طرق لعلاج فيروس نقص المناعة البشرية | |
EA202190858A1 (ru) | Безопасный и эффективный способ лечения язвенного колита с помощью антител к il-12/il-23 | |
MX2022001154A (es) | Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab. | |
MX2024005197A (es) | Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23. | |
PL431290A1 (pl) | Bezpieczna metoda podawania substancji ślimakom w formie iniekcji dożylnych |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Change/correction in patent specification |
Free format text: CHANGE/CORRECTION IN INID |